Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Epigenomics AG. (7/6/17). "Press Release: Epigenomics AG Issues Change in Guidance for Financial Year 2017".

Organisation Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
Products Product Epi proColon® blood test
  Product 2 molecular diagnostics
Person Person Vogt, Peter (Epigenomics 201601 Investor + Public Relations)

Epigenomics AG (FSE: ECX; OTCQX: EPGNY) today lowered its financial outlook for the financial year 2017.

Based on lower than expected revenues in the first half of 2017 (H1 2017: approximately EUR 0.5 million), and the continued lack of reimbursement coverage anticipated for the remainder of the year in the U.S. market, Epigenomics now expects 2017 group revenues to be in the range of EUR 1.0 to 1.5 million (previously: about EUR 2.5 million).

Due to lower anticipated revenues and potentially other cost items, adjusted EBITDA (before share-based payment expenses) is expected to be in the range of EUR -12.5 to -14.0 million (previously: EUR -12.0 to -13.5 million).

Epigenomics AG currently expects to publish its 2017 half-year financial report on August 9, 2017.


Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail:

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise

Record changed: 2023-06-05


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for Epigenomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top